Remit - To appraise the clinical and cost effectiveness of crizanlizumab within its marketing authorisation for preventing sickle cell crises in sickle cell disease
Status Proposed
Process STA 2018
ID number 1406

Provisional Schedule

Committee meeting: 1 04 November 2020
Expected publication 24 March 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Novartis (crizanlizumab)
Others Department of Health and Social Care
  NHS England
  NHS Halton CCG
  NHS Lewisham CCG
  Welsh Government
Patient carer groups Action for Sick Children
  Black Health Agency
  Contact a Family
  Equalities National Council
  Genetic Alliance UK
  Muslim Council of Britain
  National Children’s Bureau
  Pain UK
  Sickle Cell and Young Stroke Survivors (SCYSS)
  Sickle Cell Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The UK Thalassaemia Society
Professional groups Association of Genetic Nurses & Counsellors
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Society for Gene and Cell Therapy
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Human Genetics
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics and Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Forum on Haemoglobin Disorders
  UK Genetic Testing Network
  United Kingdom National Screening Committee


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Bristol-Myers Squibb (hydroxycarbamide)
  Medac GmbH (hydroxycarbamide)
  Nordic Pharma Limited (hydroxycarbamide)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Cystic Fibrosis & Genetic Disorders Group
  Cochrane Haematological Malignancies Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
03 December 2019 Following a regulatory update from the company, Novartis Pharmaceuticals, the timings for this appraisal have been amended, The first committee meeting has been rescheduled to 4 November 2020.
25 October 2019 Invitation to participate
22 March 2019 - 19 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance